Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130


PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.

Yuan K, Sun Y, Zhou T, McDonald J, Chen Y.

Clin Cancer Res. 2013 Sep 1;19(17):4750-9. doi: 10.1158/1078-0432.CCR-13-0516. Epub 2013 Jul 5.


Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.

Yuan K, Yong S, Xu F, Zhou T, McDonald JM, Chen Y.

Oncotarget. 2015 Sep 22;6(28):25308-19. doi: 10.18632/oncotarget.4490.


PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.

Karpel-Massler G, Pareja F, Aimé P, Shu C, Chau L, Westhoff MA, Halatsch ME, Crary JF, Canoll P, Siegelin MD.

PLoS One. 2014 Dec 22;9(12):e114583. doi: 10.1371/journal.pone.0114583. eCollection 2014.


Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.

Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, Hess AD, Smith BD, Karp JE, Kaufmann SH.

J Biol Chem. 2014 Jul 25;289(30):20543-58.


Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5535s-5543s.


Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ.

Clin Cancer Res. 2008 Apr 1;14(7):2180-9. doi: 10.1158/1078-0432.CCR-07-1392.


The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.

Yang SZ, Xu F, Zhou T, Zhao X, McDonald JM, Chen Y.

J Biol Chem. 2017 Jun 23;292(25):10390-10397. doi: 10.1074/jbc.M117.786830. Epub 2017 May 5.


Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM.

J Gastrointest Surg. 2006 Nov;10(9):1291-300; discussion 1300.


Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.

van Geelen CM, Pennarun B, Le PT, de Vries EG, de Jong S.

BMC Cancer. 2011 Jan 27;11:39. doi: 10.1186/1471-2407-11-39.


Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.

Kim EY, Yu JS, Yang M, Kim AK.

Mol Cells. 2013 Jan;35(1):32-40. doi: 10.1007/s10059-013-2175-2. Epub 2012 Dec 4.


Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.

Arafat W, Zhou T, Naoum GE, Buchsbaum DJ.

J Egypt Natl Canc Inst. 2015 Dec;27(4):205-15. doi: 10.1016/j.jnci.2015.08.003. Epub 2015 Sep 16.


Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.

Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 15;12(4):335-48. Epub 2011 Aug 15.


Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

Kim H, Zhai G, Samuel SL, Rigell CJ, Umphrey HR, Rana S, Stockard CR, Fineberg NS, Zinn KR.

Mol Cancer Ther. 2012 Feb;11(2):405-15. doi: 10.1158/1535-7163.MCT-11-0581. Epub 2011 Dec 27.


Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, Fulda S.

Cancer Res. 2008 Oct 1;68(19):7956-65. doi: 10.1158/0008-5472.CAN-08-1296.


Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.

Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, Toyoda E, Kawaguchi Y, Uemoto S.

J Surg Res. 2007 Oct;142(2):281-6. Epub 2007 Jul 19.


Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.

Lin T, Ding Z, Li N, Xu J, Luo G, Liu J, Shen J.

Eur J Cancer. 2011 Aug;47(12):1890-907. doi: 10.1016/j.ejca.2011.04.004. Epub 2011 May 10.


The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines.

Sahu RP, Batra S, Kandala PK, Brown TL, Srivastava SK.

Cancer Chemother Pharmacol. 2011 Feb;67(2):481-7. doi: 10.1007/s00280-010-1463-1. Epub 2010 Sep 17.


Caspase-dependent molecular mechanisms of anti-human DR5 monoclonal antibody mDRA-6 inducing apoptosis of human leukemia Jurkat cells.

Du YW, Liu GC, Wang J, Zhao YP, Li SL, Chen JG, Jiang Q, Cai J, Ma YF.

Ai Zheng. 2009 Feb;28(2):112-6. Epub 2009 Feb 27.


Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.

Bevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi A, Amm H, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2011 Apr;121(1):193-9. doi: 10.1016/j.ygyno.2010.11.046. Epub 2011 Jan 5.


Supplemental Content

Support Center